Báo cáo khoa học: Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours pot

REVIEW ARTICLE Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours S Toffoli and C Michiels Laboratory of Biochemistry and Cellular Biology (URBC), University of Namur – FUNDP, Belgium Keywords apoptosis; cancer; chemoresistance; endothelial cell; hypoxia-inducible factor-1; intermittent hypoxia; radioresistance; reactive oxygen species; reoxygenation; tumor cell Correspondence C Michiels, Laboratory of Biochemistry and Cellular Biology (URBC), University of Namur – FUNDP, 61 rue de Bruxelles, 5000 Namur, Belgium Fax: +32 81 72 41 35 Tel: +32 81 72 41 31 E-mail: carine.michiels@fundp.ac.be Solid tumours are complex structures in which the interdependent relationship between tumour and endothelial cells modulates tumour development and metastasis dissemination The tumour microenvironment plays an important role in this cell interplay, and changes in its features have a major impact on tumour growth as well as on anticancer therapy responsiveness Different studies have shown irregular blood flow in tumours, which is responsible for hypoxia and reoxygenation phases, also called intermittent hypoxia Intermittent hypoxia induces transient changes, the impact of which has been underestimated for a long time Recent in vitro and in vivo studies have shown that intermittent hypoxia could positively modulate tumour development, inducing tumour growth, angiogenic processes, chemoresistance, and radioresistance In this article, we review the effects of intermittent hypoxia on tumour and endothelial cells as well as its impacts on tumour development (Received March 2008, accepted April 2008) doi:10.1111/j.1742-4658.2008.06454.x Introduction Hypoxia is increasingly perceived as one of the tumour microenvironment features favouring tumour cell survival, and also resistance to chemotherapy and radiotherapy Hypoxia is defined as a decrease in oxygen level within the tissue However, recent studies have shown that the time frame within which this decrease occurs and, more importantly, its duration may vary greatly from one tumour to another, or even from one area to another within the same tumour These observations have led to the definition of two kinds of hypoxia: chronic hypoxia and intermittent hypoxia Intermittent and chronic hypoxia in solid tumours Chronic hypoxia in tumours, first described in 1955 [1,2], results from limitation of the diffusion of oxygen Oxygen diffuses to a distance of 100–150 lm from blood vessels in normal and malignant tissues At a greater distance, the oxygen tension becomes close to zero, and cells become hypoxic [1] In parallel with chronic hypoxia, it was suggested in 1979 that transient hypoxia or intermittent hypoxia could also appear in tumours, due to the temporary ‘closure’ of blood vessels [3] The existence of acute hypoxia events in tumours was shown a few years later, with the Abbreviations AP-1, activator protein-1; ARNT, aryl hydrocarbon receptor nuclear translocator; EPR, electron paramagnetic resonance; HIF-1, hypoxiainducible factor-1; NF-jB, nuclear factor kappaB; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS 2991 Intermittent hypoxia in cancer S Toffoli and C Michiels demonstration that intermittent hypoxia resulted from transient changes in blood flow [1,4,5] Histological analysis of tumour blood vessels showed that structural abnormalities were responsible for this irregular blood flow Indeed, tumour blood vessels are often tortuous and dilated, with excessive branching and numerous dead ends [6] Moreover, compression of these vessels by tumour cells, associated with the immaturity of the tumour vascular network, which is characterized by an absence of or a loose association with mural cells, pericytes and vascular smooth muscle cells, could also play a role in the heterogeneity of the blood flow [7–9] The blood flow stop periodicity, depending on the architectural complexity and maturation level of the tumour vascular network, is very variable from one tumour to another, and also within the same tumour [10,11] Therefore, a precise duration for blood flow interruption in tumours cannot be given However, studies of murine and human tumours have shown that the blood flow fluctuations observed in these tumours could vary from several minutes to more than h in duration [10–16] These blood flow irregularities in tumours can be demonstrated by different methods Direct real-time measurement in vivo of tumour blood flow fluctuations can be performed by the use of microprobes that are directly implanted in tumours Different microprobe systems can be used to study the blood flow fluctuations One of the most used microprobes is the Eppendorf polarographic needle electrode, which allows measurement of the oxygen partial pressure (po2) within tissues [12,17] Polarographic oxygen microelectrode functioning is based on reduction of oxygen at the surface of a cathode by applying a negative voltage between the cathode and the anode The reduction current measured with this kind of electrode is proportional to the number of oxygen molecules being reduced, and diminishes when blood flow is decreased or interrupted [18,19] Other microprobes, such as the OxyLite laser Doppler probe, allow monitoring of tumour blood perfusion [14] These probes illuminate the tissue under observation with single-frequency light from optical fibres coupled to a sensor Mobile red blood cells scatter the monochromatic light and generate a signal that is proportional to the mean erythrocyte velocity multiplied by the number of moving erythrocytes within the sampling volume [20,21] This signal decreases when the blood flow diminishes or stops, and vice versa However, the spatial resolution of these techniques is low, and the use of polarographic or laser Doppler microprobes is restricted to easily accessible tumours [22] For less accessible 2992 neoplasms, the direct real-time measurement in vivo of oxygen tension is performed by the use of imaging techniques [18,22,23], most of which are based on magnetic resonance Blood oxygen level-dependent magnetic resonance imaging and electron paramagnetic resonance (EPR) oxymetry are examples of such techniques [22–24] Blood flow modifications observed with blood oxygen level-dependent magnetic resonance imaging are based on the oxygenation status of endogenous haemoglobin This becomes paramagnetic when it is deoxygenated, and it is then detectable by magnetic resonance imaging Changes in blood flow modify the blood concentration of paramagnetic deoxyhaemoglobin and hence induce variations in the magnetic resonance signal [22,23,25,26] On the other hand, EPR oxymetry is based on the broadening of the resonance spectrum of a paramagnetic material by oxygen [27] Modifications in the EPR signal are directly correlated with the oxygen concentration, which is linked to the blood flow [18] One injection of a paramagnetic agent, such as India ink or charcoal, directly into a tumour is sufficient to allow repeated measurements to be performed over a relatively long period [18,24] Indirect measurements in vivo of tumour po2 fluctuation can also be performed by the use of a double hypoxia marker technique [11,28–30] 2-Nitroimidazoles (e.g misonidazole, EF5, CCI-103F, and pimonidazole) are commonly used as hypoxia markers These molecules are reduced by cellular nitroreductases at po2 levels below 10 mmHg to intermediates that covalently bind to cellular macromolecules [31–33] Hypoxic markers are administered in vivo separately at different times according to a pre-established timing schedule Tumour areas stained only by one marker show transient changes in hypoxia during the time interval between the injections of the two hypoxia markers [22,29] Reduced 2-nitroimidazoles can be detected by immunohistochemistry or immunofluorescence staining after the tumour resection Using radiolabelled 2-nitroimidazoles (e.g [18F]fluoromisonidazole), transiently hypoxic areas can also be detected in vivo by positron emission tomography, which is based on the detection of electromagnetic radiation emitted indirectly by the positron-emitting radioisotope [22,34] Modifications in blood flow are shown by performing scans after each hypoxia marker injection [18,22,23,35] The use of these techniques and their combination allow a better understanding of spatial and temporal changes in hypoxia in solid tumours, and also allow the linkage of these changes with other tumour microenvironmental parameters [18,22,23,35] FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS S Toffoli and C Michiels Hypoxia-inducible factor-1 (HIF) a-subunit stabilization and HIF-1 activation under intermittent hypoxia Hypoxia induces numerous changes in gene expression in normal and tumour cells [36] This adaptive response to hypoxia is orchestrated by a family of transcription factors induced by hypoxia The most important and best-studied member of this family is hypoxia-inducible factor-1 (HIF-1) HIF-1 is a heterodimeric transcription factor composed of the HIF-1a (120 kDa) and aryl hydrocarbon receptor nuclear translocator (ARNT, 94 kDa; also called HIF-1b) subunits These two subunits belong to the Per-ARNT-Sim basic–helix–loop helix family [37,38] HIF-1a and ARNT are constitutively expressed [39], but the formation of HIF-1 transcription factor in the nucleus depends on HIF-1a stabilization, which is principally O2-dependent [40] Under normoxia, HIF-1a is hydroxylated on proline 402 in the N-terminal domain and proline 564 in the C-terminal domain by prolyl-4-hydroxylases [41] These hydroxylations allow the binding of von Hippel–Lindau tumour suppressor protein on the oxygen-dependent degradation (ODD) domain of HIF-1a [42] von Hippel–Lindau tumour suppressor protein acts as the substrate recognition protein of the E3 ubiquitin ligase complex [43], and induces the ubiquitination of HIF-1a on its N-terminal and C-terminal domains (amino acids 390–417 and 549–582, respectively) [41] This ubiquitination targets HIF-1a for proteasomal degradation On the other hand, under hypoxic conditions, the prolyl hydroxylase activity decreases and the degradation pathway described above is interrupted [44] HIF-1a therefore rapidly accumulates and translocates into the nucleus, where, after dimerization with ARNT, it induces the transcription of target genes involved, notably, in glycolysis (e.g the glyceraldehyde-3-phosphate dehydrogenase gene) and angiogenesis [e.g the vascular endothelial growth factor (VEGF) gene] [45], thus allowing cells to adapt to hypoxia [46] The stabilization of HIF-1a and activation of HIF-1 have been widely studied under chronic hypoxia The new interest in intermittent hypoxia in recent years has led us to consider again this point: can the succession of short hypoxia and reoxygenation phases, typical of intermittent hypoxia, also stabilize HIF-1a and activate HIF-1? In the absence of oxygen, HIF-1a is rapidly stabilized, and short, intermittent hypoxia periods can be sufficient to induce HIF-1 Indeed, Yuan et al showed, in vitro, HIF-1a stabilization during intermittent hypoxia (cycles of 30 s of hypoxia followed by of reoxygenation) [47] This increase in HIF-1a abun- Intermittent hypoxia in cancer dance was dependent on the number of intermittent hypoxia cycles The kinetics used by Yuan et al undoubtedly demonstrate that short hypoxia–reoxygenation cycles can induce HIF-1a stabilization However, considering these kinetics, the increase in abundance of HIF-1a during intermittent hypoxia cycles could be due to an accumulation of HIF-1a subunit during each cycle, and not to an increase in its stabilization Indeed, although HIF-1a may be extremely rapidly degraded when cells are reoxygenated, its degradation after of reoxygenation was not assayed by Yuan et al Furthermore, Berra et al showed that HIF-1a could still be detected after of reoxygenation in HeLa cells incubated for h or or h under hypoxia They showed that the half-life of HIF-1a is inversely proportional to the duration of hypoxic stress [48], suggesting that long hypoxia periods could decrease HIF-1a stability Other recent studies have also shown an increase in HIF-1a abundance in the course of intermittent hypoxia cycles, using longer cycles of h of hypoxia followed by 30 of reoxygenation [49,50] The times used in these studies allowed the demonstration of complete HIF-1a degradation after each cycle of 30 of reoxygenation, showing that HIF-1a had not accumulated in the course of intermittent hypoxia cycles, and therefore that it is its stabilization that is increased in these conditions [50] HIF-1a stabilization does not always translate into HIF-1 activity One can therefore ask whether hypoxia periods interrupted by reoxygenation periods can be sufficient to induce the transcription of HIF-1 target genes HIF-1a degradation after each reoxygenation makes HIF-1 inactive In these circumstances, HIF-1 can only be transcriptionally active during the hypoxia phases, which can be short Reporter assays showed a significant gradual increase in hypoxia response element (HRE) promoter activity in PC12 cells incubated under intermittent hypoxia, in the course of hypoxia–reoxygenation cycles [47] Interestingly, with the same incubation time, HIF-1 transcriptional activity observed under intermittent hypoxia was almost equal to HIF-1 transcriptional activity observed under chronic hypoxia [50] Moreover, with the same incubation time under hypoxia (duration of reoxygenation under intermittent hypoxia was not considered in this case), Yuan et al showed higher HIF-1 transcriptional activity in comparison to chronic hypoxia [47] Although intermittent hypoxia can induce, like chronic hypoxia, HIF-1a stabilization as well as HIF-1 transcriptional activity, some differences can be seen between these two kinds of hypoxia It was shown in PC12 cells and EAhy926 endothelial cells that, under FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS 2993 Intermittent hypoxia in cancer S Toffoli and C Michiels Fig Effects of intermittent hypoxia and chronic hypoxia on HIF-1a stabilization and HIF-1 target gene transcription transient hypoxia, extracellular signal-related kinase ⁄ mitogen-activated protein kinases and phosphoinositide-3-kinase are not required for HIF-1 stabilization and transcriptional activity [47,50], whereas the inhibition of these kinases under chronic hypoxia impaired HIF-1 target gene expression [51,52] On the other hand, at least in endothelial cells, protein kinase A is involved in HIF-1a phosphorylation under intermittent hypoxia but not under chronic hypoxia, and protein kinase A inhibition decreased the transcription of HIF-1 target genes [50] These results suggest that the pathways regulating HIF-1 activity under chronic or intermittent hypoxia are different Figure shows a brief comparison of HIF-1a stabilization and HIF-1 activation under intermittent hypoxia and chronic hypoxia Tumour resistance induced by intermittent hypoxia The effects of chronic hypoxia have been extensively studied, and it has been clearly demonstrated that chronic hypoxia protects tumour cells from apoptosis induced by radiotherapy and chemotherapy [53–60] Recent studies have shown that intermittent hypoxia could also protect tumour cells from anticancer treatments Martinive et al showed, in vivo, a decrease in tumour cell apoptosis in transplantable liver tumour implanted in mice subjected to cycles of intermittent hypoxia before irradiation (10 Gy) with respect to mice kept under normoxia [49] This inhibition of apoptosis under transient hypoxia was also observed in vitro in 2994 FsaII fibrocarcinoma cells and B16 melanoma cells [49] Moreover, Dong & Wang demonstrated the possibility of death-resistant cell selection by the repetition of hypoxia episodes [61] Such selected cells were shown to be resistant to cell death induced by different types of molecules, such as azide, cisplatin and staurosporine [61] Transient hypoxia could also render tumours more invasive Cairns et al observed a highly significant increase in the number of lung micrometastases in KHT tumour-bearing mice exposed to 12 cycles per day (for 8–15 days) of 10 of hypoxia followed by 10 of reoxygenation, in comparison to control mice Interestingly, no increase in lung micrometastasis was observed in mice exposed to chronic hypoxia [15], suggesting again that intermittent hypoxia has different effects from chronic hypoxia In addition, it was shown by Durand & AquinoParsons that blood flow decreases could transiently arrest the division of tumour cells in S-phase [62] These cells are the main targets of chemotherapy, and the arrest of their cell cycle during S-phase reduces considerably their sensitivity to antiproliferative drugs, but it also implies a more rapid initiation of tumour cell repopulation when the blood flow restarts [62] More generally, the transient cessation of tumour blood flow reduces tumour cell exposure to the most highly diffusible anticancer agents, but also reduces their sensitivity to radiotherapy because of the decrease in oxygen supply during tumour irradiation [57,62] The protection against antitumour treatment can also be linked to a particular phenotype acquired by the cells in the course of intermittent hypoxia phases An FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS S Toffoli and C Michiels example of such acquired resistance is described by Dong & Wang [61]: upregulation of Bcl-XL has been observed in immortalized rat kidney epithelial cells exposed to repeated periods of hypoxia It was shown in these cells that Bcl-XL could directly interact with the proapoptotic molecule Bax at the mitochondrial level, impeding Bax oligomerization and cytochrome c release, and hence preventing cell apoptosis [61] Genetic instability due to abnormal DNA metabolism linked to impaired activity of enzymes such as topoisomerases, helicases and ligases is often observed in hypoxic tumours [63] Strand breaks, translocations, transversions and other chromosomal rearrangements observed in these conditions can also be responsible for tumour resistance Reynolds et al showed that hypoxia could induce a 3–4-fold elevation in mutation frequency, and higher levels of mutagenesis were observed in cells exposed multiple times to hypoxia [63], suggesting that exposure of cells to transient hypoxia could also induce resistance to antitumour treatments by this mechanism Moreover, oxidative injuries generated by reoxygenation in the course of intermittent hypoxia phases can also be responsible for DNA damage through an increase in 8-oxoguanine, which has been shown to miscode for A and lead to C:G to A:T transversions [64] Reactive oxygen species (ROS) generated during the reoxygenation periods can also play an important role, modifying gene expression through the regulation of the activity of some transcription factors, such as activator protein-1 (AP-1) or nuclear factor kappaB (NF-jB) AP-1 is known to play a pivotal role in tumorigenesis, regulating the expression and function of cell cycle regulators such cyclin D1, p53, p21, p19, and p16 Moreover, its activity was shown to increase in multiple human tumour types, and its inhibition can block tumour promotion, transformation, progression, and invasion [65] AP-1 activation was shown in PC12 cells under intermittent hypoxia, and was clearly associated with ROS production and, more particularly, with superoxide (O2Ỉ–) anion generation [66] Furthermore, it was shown that AP-1 activation involved c-fos, the activation of which persisted for several hours after the intermittent hypoxia ‘stimulus’ [66] Deregulation of c-fos and c-jun proteins can induce transformation in vivo [67], and c-fos upregulation was shown in tumour formation and, more particularly, in liver tumour development In this kind of tumour, AP-1 and c-fos were shown to be able to downregulate tumour suppressor genes and favour angiogenesis and tumour invasiveness [68] Therefore, AP-1 activation under intermittent hypoxia, associated Intermittent hypoxia in cancer with c-fos upregulation, could promote tumour development NF-jB can also be activated by ROS [69] ROS production during the reoxygenation periods [70] might also be able to activate NF-jB Ryan et al showed in HeLa cells and bovine aortic endothelial cells that transient hypoxia activated NF-jB in a number of hypoxia–reoxygenation cycles in an ROS-dependent manner [71] Despite the potential production of ROS during reoxygenation concomitant with NF-jB activation, these authors suggested that NF-jB activation under intermittent hypoxia was not linked to ROS production, because no decrease in NF-jB activation in the presence of the ROS scavenger N-acetyl-l-cysteine was observed [71] However, inhibition of NF-jB activation by N-acetyl-l-cysteine has been shown to occur not through ROS-dependent mechanisms, but rather through inhibition of tumour necrosis factorstimulated signal transduction by lowering tumour necrosis factor receptor affinity [72,73] or through inhibition of its DNA-binding activity [74] Therefore, involvement of ROS in NF-jB activation under intermittent hypoxia cannot be completely excluded It has to be noted that NF-jB activation by ROS is extremely cell type-dependent Beyond the question of the regulation mechanisms of NF-jB, its activation under intermittent hypoxia remains a critical point, because NF-jB plays an important role in tumour development through its ability to induce the transcription of genes coding for apoptosis inhibitor factors (cIAPs, Bcl-XL, FLICE), proproliferation molecules (interleukin-2, G1 cyclins), proangiogenic factors (VEGF, interleukin-8), and enzymes that lead to extracellular matrix degradation (matrix metalloproteases) [75–78] In addition, NF-jB activation was reported as an early event in malignant transformation in vitro [79], and continuous activation of NF-jB was also shown in many kinds of solid tumours [80] Conversely, NF-jB inhibition impairs tumour development NF-jB inhibition in prostate cancer in mice led to a marked reduction in the growth of tumour, demonstrating again the important role played by this transcription factor in tumour development [80] HIF-1 activation in tumours is often associated with a poor prognosis It allows the tumour cells to survive in the absence of oxygen, regulating their cell metabolism and inducing the production of prosurvival molecules, but also inducing the formation of new blood vessels, favouring metastasis [81] HIF-1 activation is always associated with hypoxia, but it was shown that the production of ROS under normoxia was also able to stabilize HIF-1a subunit and contribute to HIF-1 activation [82] The production of ROS during the FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS 2995 Intermittent hypoxia in cancer S Toffoli and C Michiels reoxygenation periods under intermittent hypoxia could then also influence HIF-1 activity However, HIF-1a subunit degradation is always observed during reoxygenation after incubation under chronic or transient hypoxia Therefore, HIF-1 activation during reoxygenation after a hypoxia period should be impaired in this case Paradoxically, it was shown that reoxygenation could stimulate HIF-1 signalling Increases in the translation of HIF-1 target genes and HRE–green fluorescent protein construction transcripts were observed after reoxygenation, despite the complete degradation of HIF-1a [83,84] This peculiar observation was explained by Moeller et al., who showed that reoxygenation could enhance downstream HIF-1 signalling by depolymerizing stress granules They showed that a pool of HIF-1-regulated transcripts were kept untranslated in the course of hypoxia in stress granules that were depolymerized during reoxygenation, allowing the rapid translation of sequestrated transcripts under normoxia [83] Interestingly, Moeller et al also observed stress granule formation in tumour cells under hypoxia as well as their degradation during reoxygenation Hence, they suggested that this post-transcriptional regulation process could help cancer cells to recover from a hypoxic shock and prepare the cells for a future insult This mechanism, the regulation of which could involve ROS, as suggested again by Moeller et al., could also explain, at least in part, the cancer cell resistance to anticancer treatment observed under intermittent hypoxia It would be interesting to investigate the involvement of stress granules in the gradual increase in the abundance of HIF-1a observed after each hypoxia step in the course of hypoxia–reoxygenation cycles Effects of intermittent hypoxia on tumour vasculature Tumour blood vessel formation is essential for tumour development As well as comprising a tumour cell dissemination pathway in the body, tumour blood vessels supply to cancer cells the oxygen and nutrients essential for their survival and proliferation In the absence of angiogenesis and new blood vessel formation, tumour growth is restricted, and the tumour size remains ‘microscopic’, generally not increasing beyond 0.5 mm, even in the case of a highly proliferative tumour, in which cell division is balanced by cell apoptosis induced by unfavourable survival conditions [85– 88] In these circumstances, in situ tumours can remain dormant ‘indefinitely’ in the absence of angiogenesis [89] Indeed, antiangiogenic treatments were shown to be able to impair or slow down tumour development 2996 and to reduce the volume of some solid tumours [90– 92] One of the main targets of these treatments comprises the endothelial cells One endothelial cell can control the survival of approximately 50–100 tumour cells [93] Therefore, the destruction of a few endothelial cells may induce the death of a large number of tumour cells Moreover, it was shown that endothelial cell suppression could also mediate apoptosis in drugresistant tumour cells [94,95] The role played by the tumour vascular network is thus critical in the development of a tumour, and therefore the effects of the tumour microenvironment on the cells constituting this network, i.e the endothelial cells, must also be considered Indeed, the tumour environment induces faster endothelial cell proliferation than in normal tissue, and the turnover of endothelial cells in tumours was estimated to be 20–2000 times faster [96] Moreover, significant differences have been shown in the transcriptome of tumour endothelial cells in comparison to endothelium in surrounding normal tissue [97–99] In addition, tumour cells can favour endothelial cell survival within tumours by the production of VEGF, and particularly after irradiation [100] As described previously in this review, intermittent hypoxia influences tumour cell behaviour Transient hypoxia also affects endothelial cells It was shown in vivo that intermittent hypoxia had a proangiogenic effect An increase in capillary density in mouse brains was observed after the repetition of cycles of of hypoxia followed by of reoxygenation for weeks [101] Moreover, in vitro, an increase in endothelial cell migration and formation of tubes was also reported under intermittent hypoxia [49] Therefore, transient hypoxia could increase angiogenic processes also in tumours Furthermore, it was observed that endothelial cells become, like tumour cells, radioresistant after an intermittent hypoxia preconditioning In vitro, an increase in the survival of endothelial cells was observed after irradiation (2 Gy) when intermittent hypoxia preconditioning was performed [49] This protective effect of intermittent hypoxia against radiotherapy on endothelial cells was shown to be HIF-1-dependent Indeed, a decrease in endothelial cell survival after a low level of irradiation (2 Gy) on cells previously incubated under intermittent hypoxia was shown when HIF-1a was silenced by small interfering RNA [49] Endothelial cell radioprotection through the repetition of hypoxia–reoxygenation cycles was also observed in vivo Terminal dUTP nick-end labelling assays showed a decrease in the number of apoptotic cells in the vasculature of transplantable liver tumour borne by mice when rodents were submitted to three cycles of h of hypoxia followed by 30 of FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS S Toffoli and C Michiels reoxygenation before tumour irradiation (10 Gy) [49] Interestingly, chronic hypoxia incubation before the irradiation did not protect endothelial cells against apoptosis: in contrast to intermittent hypoxia, it even drastically increased cell apoptosis [49] Moeller et al also showed in vivo a radioprotective effect of hypoxia ⁄ reoxygenation in endothelial cells after irradiation [83] They suggested that this radioprotection was induced by the secretion of endothelial cell-radioprotective cytokines by tumour cells after reoxy- Intermittent hypoxia in cancer genation They showed that tumour cell-conditioned medium recovered after incubation under hypoxia followed by reoxygenation was more radioprotective for endothelial cells than conditioned medium from tumour cells incubated under normoxia, normoxia with radiation, or hypoxia without reoxygenation [83] Moreover, it was shown that this endothelial cell radioprotection mediated by tumour cells after hypoxia–reoxygenation was also HIF-1-dependent Indeed, no significant endothelial cell radioprotective Fig Schematic representation of the effects of intermittent hypoxia on cancer cells and endothelial cells within a tumour Fig Schematic representation of the effects of HIF-1 activation under intermittent hypoxia on cancer cells and endothelial cells within a tumour FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS 2997 Intermittent hypoxia in cancer S Toffoli and C Michiels effect was observed when conditioned medium was taken from HIF-1-incompetent tumour cells [83] Therefore, these results suggest that intermittent hypoxia protects endothelial cells in a direct manner by acting directly on the endothelial cell phenotype, as observed by Martinive et al in vitro [49], and also by indirect pathways involving secreted molecules released from tumour cells, as suggested by Moeller et al [83] Conclusion Until now, most attention has been paid to chronic hypoxia However, during the last few years, a new concept has arisen, showing first that changes in po2 level are not always sustained in tumours but that they can be transient, and second that intermittent hypoxia can exert effects that are different from those induced by chronic hypoxia Both tumour cells and endothelial cells are affected by intermittent hypoxia, which can be perceived as the consequence of different stresses resulting from repeated combinations of hypoxia and reoxygenation periods, which may induce different cell responses In contrast, chronic hypoxia causes a prolonged and unique modification of the cell environment Figures and schematically summarize the effects of intermittent hypoxia The major conclusion drawn from these observations is the intricate interplay between tumour cells and endothelial cells, each favouring the survival of the other This delicate ballet has to be understood in detail in order to allow the design of new therapies targeting these processes Acknowledgements ´ ´ ´ Sebastien Toffoli is recipient of a FNRS-Televie grant Carine Michiels is research director of FNRS (Fonds National de la Recherche Scientifique, Belgium) This article presents results of the Belgian Programme on Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister’s Office, Science Policy Programming The responsibility is assumed by its authors References Brown JM (1990) Tumor hypoxia, drug resistance, and metastases J Natl Cancer Inst 82, 338–339 Thomlinson RH & Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy Br J Cancer 9, 539–549 Brown JM (1979) Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation Br J Radiol 52, 650–656 2998 Chaplin DJ, Durand RE & Olive PL (1986) Acute hypoxia in tumors: implications for modifiers of radiation effects Int J Radiat Oncol Biol Phys 12, 1279– 1282 Chaplin DJ, Olive PL & Durand RE (1987) Intermittent blood flow in a murine tumor: radiobiological effects Cancer Res 47, 597–601 Bergers G & Benjamin LE (2003) Tumorigenesis and the angiogenic switch Nat Rev Cancer 3, 401–410 Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK & McDonald DM (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors Am J Pathol 160, 985–1000 Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E & Jain RK (2004) Pathology: cancer cells compress intratumour vessels Nature 427, 695 Baudelet C, Cron GO, Ansiaux R, Crokart N, DeWever J, Feron O & Gallez B (2006) The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors NMR Biomed 19, 69–76 10 Chaplin DJ & Hill SA (1995) Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours Br J Cancer 71, 1210–1213 11 Bennewith KL & Durand RE (2004) Quantifying transient hypoxia in human tumor xenografts by flow cytometry Cancer Res 64, 6183–6189 12 Braun RD, Lanzen JL & Dewhirst MW (1999) Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats Am J Physiol 277, H551–H568 13 Hill SA, Pigott KH, Saunders MI, Powell ME, Arnold S, Obeid A, Ward G, Leahy M, Hoskin PJ & Chaplin DJ (1996) Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes Br J Cancer Suppl 27, S260–S263 14 Pigott KH, Hill SA, Chaplin DJ & Saunders MI (1996) Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry Radiother Oncol 40, 45–50 15 Cairns RA, Kalliomaki T & Hill RP (2001) Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors Cancer Res 61, 8903–8908 16 Cardenas-Navia LI, Yu D, Braun RD, Brizel DM, Secomb TW & Dewhirst MW (2004) Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing Cancer Res 64, 6010– 6017 17 Nordsmark M, Bentzen SM & Overgaard J (1994) Measurement of human tumour oxygenation status by a polarographic needle electrode An analysis of interand intratumour heterogeneity Acta Oncol 33, 383–389 18 Foo SS, Abbott DF, Lawrentschuk N & Scott AM (2004) Functional imaging of intratumoral hypoxia Mol Imaging Biol 6, 291–305 FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS S Toffoli and C Michiels 19 Nozue M, Lee I, Yuan F, Teicher BA, Brizel DM, Dewhirst MW, Milross CG, Milas L, Song CW, Thomas CD et al (1997) Interlaboratory variation in oxygen tension measurement by Eppendorf ‘Histograph’ and comparison with hypoxic marker J Surg Oncol 66, 30–38 20 Jakobsson A & Nilsson GE (1993) Prediction of sampling depth and photon pathlength in laser Doppler flowmetry Med Biol Eng Comput 31, 301–307 21 Nilsson GE, Tenland T & Oberg PA (1980) Evaluation of a laser Doppler flowmeter for measurement of tissue blood flow IEEE Trans Biomed Eng 27, 597–604 22 Ljungkvist AS, Bussink J, Kaanders JH & van der Kogel AJ (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers Radiat Res 167, 127–145 23 Padhani AR, Krohn KA, Lewis JS & Alber M (2007) Imaging oxygenation of human tumours Eur Radiol 17, 861–872 24 Gallez B, Baudelet C & Jordan BF (2004) Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications NMR Biomed 17, 240–262 25 Landuyt W, Hermans R, Bosmans H, Sunaert S, Beatse E, Farina D, Meijerink M, Zhang H, Van Den Bogaert W, Lambin P et al (2001) BOLD contrast fMRI of whole rodent tumour during air or carbogen breathing using echo-planar imaging at 1.5 T Eur Radiol 11, 2332–2340 26 Ogawa S, Lee TM, Kay AR & Tank DW (1990) Brain magnetic resonance imaging with contrast dependent on blood oxygenation Proc Natl Acad Sci USA 87, 9868–9872 27 Mahy P, De Bast M, Gallez B, Gueulette J, Koch CJ, Scalliet P & Gregoire V (2003) In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors Radiother Oncol 67, 53–61 28 Dewhirst MW, Braun RD & Lanzen JL (1998) Temporal changes in PO2 of R3230AC tumors in Fischer-344 rats Int J Radiat Oncol Biol Phys 42, 723–726 29 Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J & Van Der Kogel AJ (2000) Changes in tumor hypoxia measured with a double hypoxic marker technique Int J Radiat Oncol Biol Phys 48, 1529– 1538 30 Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA & van der Kogel AJ (2000) Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis Int J Radiat Oncol Biol Phys 48, 571–582 31 Arteel GE, Thurman RG & Raleigh JA (1998) Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the Intermittent hypoxia in cancer 32 33 34 35 36 37 38 39 40 41 42 43 pyridine nucleotide redox state Eur J Biochem 253, 743–750 Joseph P, Jaiswal AK, Stobbe CC & Chapman JD (1994) The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles Int J Radiat Oncol Biol Phys 29, 351–355 Melo T, Ballinger JR & Rauth AM (2000) Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia Biochem Pharmacol 60, 625–634 Saleem A, Charnley N & Price P (2006) Clinical molecular imaging with positron emission tomography Eur J Cancer 42, 1720–1727 Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA et al (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography Int J Radiat Oncol Biol Phys 33, 391–398 Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL et al (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers PLoS Med 3, e47 Wang GL, Jiang BH, Rue EA & Semenza GL (1995) Hypoxia-inducible factor is a basic-helix-loop-helixPAS heterodimer regulated by cellular O2 tension Proc Natl Acad Sci USA 92, 5510–5514 Wang GL & Semenza GL (1995) Purification and characterization of hypoxia-inducible factor J Biol Chem 270, 1230–1237 Salceda S & Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin–proteasome system under normoxic conditions Its stabilization by hypoxia depends on redox-induced changes J Biol Chem 272, 22642–22647 Semenza GL (2001) HIF-1, O(2), and the PHDs: how animal cells signal hypoxia to the nucleus Cell 107, 1–3 Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS & Kaelin WG Jr (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing Science 292, 464–468 Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ & Maxwell PH (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel–Lindau tumor suppressor protein J Biol Chem 275, 25733–25741 Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS 2999 Intermittent hypoxia in cancer 44 45 46 47 48 49 50 51 52 53 54 55 S Toffoli and C Michiels M, Schofield CJ et al (2001) Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation Science 292, 468– 472 Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH & Gassmann M (2001) Induction of HIF-1alpha in response to hypoxia is instantaneous FASEB J 15, 1312–1314 Jiang BH, Rue E, Wang GL, Roe R & Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor J Biol Chem 271, 17771–17778 Wenger RH (2000) Mammalian oxygen sensing, signalling and gene regulation J Exp Biol 203, 1253–1263 Yuan G, Nanduri J, Bhasker CR, Semenza GL & Prabhakar NR (2005) Ca2+ ⁄ calmodulin kinase-dependent activation of hypoxia inducible factor transcriptional activity in cells subjected to intermittent hypoxia J Biol Chem 280, 4321–4328 Berra E, Richard DE, Gothie E & Pouyssegur J (2001) HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation FEBS Lett 491, 85–90 Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Gregoire V, Michiels C, Dessy C & Feron O (2006) Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies Cancer Res 66, 11736–11744 Toffoli S, Feron O, Raes M & Michiels C (2007) Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKAdependent regulation of HIF-1alpha Biochim Biophys Acta 1773, 1558–1571 Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M & Michiels C (2003) Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase ⁄ Akt ⁄ glycogen synthase kinase 3beta pathway in HepG2 cells J Biol Chem 278, 31277–31285 Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J & Michiels C (2000) ERK activation upon hypoxia: involvement in HIF-1 activation FEBS Lett 468, 53–58 Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW & Giaccia AJ (1996) Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumours Nature 379, 88–91 Cosse JP, Sermeus A, Vannuvel K, Ninane N, Raes M & Michiels C (2007) Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines Mol Cancer 6, 61–76 Lee SM, Lee CT, Kim YW, Han SK, Shim YS & Yoo CG (2006) Hypoxia confers protection against apoptosis via PI3K ⁄ Akt and ERK pathways in lung cancer cells Cancer Lett 242, 231–238 3000 56 Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG & Borea PA (2007) Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells Mol Pharmacol 72, 162–172 57 Moeller BJ, Richardson RA & Dewhirst MW (2007) Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment Cancer Metastasis Rev 26, 241–248 58 Piret JP, Lecocq C, Toffoli S, Ninane N, Raes M & Michiels C (2004) Hypoxia and CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1 Exp Cell Res 295, 340–349 59 Schnitzer SE, Schmid T, Zhou J & Brune B (2006) Hypoxia and HIF-1alpha protect A549 cells from druginduced apoptosis Cell Death Differ 13, 1611–1613 60 Song X, Liu X, Chi W, Liu Y, Wei L, Wang X & Yu J (2006) Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene Cancer Chemother Pharmacol 58, 776–784 61 Dong Z & Wang J (2004) Hypoxia selection of deathresistant cells A role for Bcl-X(L) J Biol Chem 279, 9215–9221 62 Durand RE & Aquino-Parsons C (2001) Non-constant tumour blood flow – implications for therapy Acta Oncol 40, 862–869 63 Reynolds TY, Rockwell S & Glazer PM (1996) Genetic instability induced by the tumor microenvironment Cancer Res 56, 5754–5757 64 Cheng KC, Cahill DS, Kasai H, Nishimura S & Loeb LA (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G- - - -T and A- - - -C substitutions J Biol Chem 267, 166–172 65 Matthews CP, Colburn NH & Young MR (2007) AP-1 a target for cancer prevention Curr Cancer Drug Targets 7, 317–324 66 Yuan G, Adhikary G, McCormick AA, Holcroft JJ, Kumar GK & Prabhakar NR (2004) Role of oxidative stress in intermittent hypoxia-induced immediate early gene activation in rat PC12 cells J Physiol 557, 773– 783 67 Shaulian E & Karin M (2001) AP-1 in cell proliferation and survival Oncogene 20, 2390–2400 68 Eferl R & Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis Nat Rev Cancer 3, 859–868 69 Gloire G, Legrand-Poels S & Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later Biochem Pharmacol 72, 1493–1505 70 Prabhakar NR (2001) Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms J Appl Physiol 90, 1986–1994 71 Ryan S, McNicholas WT & Taylor CT (2007) A critical role for p38 map kinase in NF-kappaB signaling FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS S Toffoli and C Michiels 72 73 74 75 76 77 78 79 80 81 82 83 during intermittent hypoxia ⁄ reoxygenation Biochem Biophys Res Commun 355, 728–733 Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M & Kikugawa K (2003) Evidence that reactive oxygen species not mediate NF-kappaB activation EMBO J 22, 3356–3366 Yang J, Su Y & Richmond A (2007) Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway Free Radic Biol Med 42, 1369–1380 Qanungo S, Wang M & Nieminen AL (2004) N-Acetyl-L-cysteine enhances apoptosis through inhibition of nuclear factor-kappaB in hypoxic murine embryonic fibroblasts J Biol Chem 279, 50455–50464 Bond M, Fabunmi RP, Baker AH & Newby AC (1998) Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NFkappa B FEBS Lett 435, 29–34 Guttridge DC, Albanese C, Reuther JY, Pestell RG & Baldwin AS Jr (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1 Mol Cell Biol 19, 5785–5799 Huang S, Robinson JB, Deguzman A, Bucana CD & Fidler IJ (2000) Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin Cancer Res 60, 5334–5339 Karin M, Cao Y, Greten FR & Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit Nat Rev Cancer 2, 301–310 Kim DW, Sovak MA, Zanieski G, Nonet G, RomieuMourez R, Lau AW, Hafer LJ, Yaswen P, Stampfer M, Rogers AE et al (2000) Activation of NF-kappaB ⁄ Rel occurs early during neoplastic transformation of mammary cells Carcinogenesis 21, 871–879 Rayet B & Gelinas C (1999) Aberrant rel ⁄ nfkb genes and activity in human cancer Oncogene 18, 6938– 6947 Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL & Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res 59, 5830–5835 Kietzmann T & Gorlach A (2005) Reactive oxygen species in the control of hypoxia-inducible factormediated gene expression Semin Cell Dev Biol 16, 474–486 Moeller BJ, Cao Y, Li CY & Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules Cancer Cell 5, 429– 441 Intermittent hypoxia in cancer 84 Vordermark D, Shibata T & Brown JM (2001) Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation Neoplasia 3, 527–534 85 Brem S, Brem H, Folkman J, Finkelstein D & Patz A (1976) Prolonged tumor dormancy by prevention of neovascularization in the vitreous Cancer Res 36, 2807–2812 86 Folkman J (2003) Angiogenesis and apoptosis Semin Cancer Biol 13, 159–167 87 Gimbrone MA Jr, Leapman SB, Cotran RS & Folkman J (1972) Tumor dormancy in vivo by prevention of neovascularization J Exp Med 136, 261–276 88 Holmgren L, O’Reilly MS & Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med 1, 149–153 89 Folkman J & Kalluri R (2004) Cancer without disease Nature 427, 787 90 Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O’Reilly T et al (2000) PTK787 ⁄ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60, 2178–2189 91 Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10, 145–147 92 Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC & Sone S (2004) Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin Clin Cancer Res 10, 7671–7676 93 Folkman J (2002) Looking for a good endothelial address Cancer Cell 1, 113–115 94 Baguley BC, Holdaway KM, Thomsen LL, Zhuang L & Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism Eur J Cancer 27, 482–487 95 Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS & Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60, 1878–1886 96 Hobson B & Denekamp J (1984) Endothelial proliferation in tumours and normal tissues: continuous labelling studies Br J Cancer 49, 405–413 97 St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B et al (2000) Genes FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS 3001 Intermittent hypoxia in cancer S Toffoli and C Michiels expressed in human tumor endothelium Science 289, 1197–1202 98 Hewett P, Popplewell A, Finney H & Murray JC (1999) Changes in microvessel endothelial cell gene expression in an in vitro human breast tumour endothelial cell model Angiogenesis 3, 221–229 99 Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ et al (2007) Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma Cancer Res 67, 1757–1768 3002 100 Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59, 3374–3378 101 Kanaan A, Farahani R, Douglas RM, Lamanna JC & Haddad GG (2006) Effect of chronic continuous or intermittent hypoxia and reoxygenation on cerebral capillary density and myelination Am J Physiol Regul Integr Comp Physiol 290, R1105–R1114 FEBS Journal 275 (2008) 2991–3002 ª 2008 The Authors Journal compilation ª 2008 FEBS ... years has led us to consider again this point: can the succession of short hypoxia and reoxygenation phases, typical of intermittent hypoxia, also stabilize HIF- 1a and activate HIF-1? In the absence... hypoxia in cancer S Toffoli and C Michiels Fig Effects of intermittent hypoxia and chronic hypoxia on HIF- 1a stabilization and HIF-1 target gene transcription transient hypoxia, extracellular signal-related... or intermittent hypoxia are different Figure shows a brief comparison of HIF- 1a stabilization and HIF-1 activation under intermittent hypoxia and chronic hypoxia Tumour resistance induced by intermittent